Nabriva Therapeutics Stock Price - NBRV

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Nabriva Therapeutics PLC NBRV NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 1.56 1.52 1.58 1.54 1.56 00:00:03
Bid Price Ask Price Spread Spread % News
1.32 1.62 0.30 18.52% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,795 538,103 $ 1.56 $ 839,415 1,232,033 1.16 - 3.27
Last Trade Time Type Quantity Stock Price Currency
17:02:57 1 $ 1.56 USD

Nabriva Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 147.49M 94.55M $ -114.78M -2.11 - 94.07M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Nabriva Therapeutics News

Loading Messages....

Latest NBRV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NBRV Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.511.621.461.57999,7840.053.31%
1 Month1.431.651.261.421,049,6660.139.09%
3 Months1.982.041.161.421,368,329-0.42-21.21%
6 Months2.232.6851.161.741,215,249-0.67-30.04%
1 Year2.,202,023-0.51-24.64%
3 Years10.8514.101.123.20655,757-9.29-85.62%
5 Years11.3917.481.123.32454,424-9.83-86.3%

Nabriva Therapeutics Description

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Your Recent History
Nabriva Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.